Lyell Immunopharma, Inc.
NASDAQ:LYEL
1.27 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2023 | 2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|---|
Operating Activities: | |||||
Net Income
| -234.632 | -183.118 | -250.219 | -204.472 | -129.377 |
Depreciation & Amortization
| 20.25 | 18.02 | 13.624 | 4.294 | 1.256 |
Deferred Income Tax
| 4.836 | 2.317 | 39.506 | -5.612 | -1.518 |
Stock Based Compensation
| 47.084 | 81.924 | 62.201 | 33.261 | 15.732 |
Change In Working Capital
| 3.421 | -82.015 | 4.015 | -0.336 | 110.808 |
Accounts Receivables
| 0 | 0 | 0 | 0 | 0 |
Inventory
| 0 | 0 | 0 | 0 | 0 |
Accounts Payables
| 1.464 | 0.667 | 0.091 | -0.278 | 1.709 |
Other Working Capital
| 1.957 | -82.682 | 3.924 | -0.058 | 109.099 |
Other Non Cash Items
| -4.653 | -6.683 | 4.624 | 11.991 | 42.573 |
Operating Cash Flow
| -163.694 | -169.555 | -126.249 | -160.874 | 39.474 |
Investing Activities: | |||||
Investments In Property Plant And Equipment
| -2.686 | -24.276 | -65.504 | -51.481 | -16.047 |
Acquisitions Net
| -186.734 | -12.736 | 673.465 | 0 | 0 |
Purchases Of Investments
| -476.88 | -406.316 | -673.465 | -43.448 | -34 |
Sales Maturities Of Investments
| 663.614 | 419.052 | 617.396 | 686.322 | 238.456 |
Other Investing Activites
| 186.734 | 12.736 | -673.465 | -864.909 | -610.842 |
Investing Cash Flow
| 184.048 | -11.54 | -121.573 | -273.516 | -422.433 |
Financing Activities: | |||||
Debt Repayment
| 0 | 0 | 0 | 0 | 0 |
Common Stock Issued
| 2.2 | 9.577 | 391.802 | 492.84 | 351.341 |
Common Stock Repurchased
| -0.457 | -0.461 | 0 | -16.05 | -0.185 |
Dividends Paid
| 0 | 0 | 0 | 0 | 0 |
Other Financing Activities
| 2.2 | 1.519 | 9.442 | 476.79 | 351.156 |
Financing Cash Flow
| 1.743 | 10.635 | 401.244 | 476.79 | 351.156 |
Other Information: | |||||
Effect Of Forex Changes On Cash
| 0 | 0 | 0 | 0 | 0 |
Net Change In Cash
| 22.097 | -170.46 | 153.422 | 42.4 | -31.803 |
Cash At End Of Period
| 145.931 | 123.834 | 294.294 | 140.872 | 98.472 |